CAPR: Block & Leviton Encourages Capricor Therapeutics Investors to Seek Appointment as Lead Plaintiff

BOSTON, MA / ACCESS Newswire / August 6, 2026 / Block & Leviton announces that a securities fraud lawsuit has been filed against Capricor Therapeutics Inc. (NASDAQ:CAPR) and certain of its executives. Investors who have lost money in their Capricor Therapeutics investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/capr. What is this all about?

According to the lawsuit, Capricor Therapeutics and certain of its executives misled investors about Deramiocel, the company's lead cell-therapy candidate for treating Duchenne muscular dystrophy, between December 17, 2025 and July 26, 2026. The complaint alleges that Capricor portrayed its Phase 3 HOPE-3 results as statistically significant and represented that the data addressed the FDA's earlier concerns, while failing to disclose that the company had changed the trial's pre-specified statistical analysis plan, that the FDA had not agreed to those changes, and that the resulting analyses risked being viewed as post-hoc and insufficient to demonstrate the drug's effectiveness.